Bristol-Myers Squibb Company (BMY)
NYSE · Healthcare · Drug Manufacturers - General
$58.81−3.83%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $120B
- P/E (trailing)
- 12.9
- Forward P/E
- 9.0
- Dividend yield
- 4.3%
- 52-week range
- $42.52 – $68.64
- 52-week change
- +36.92%
- EPS (trailing)
- $4.54
- Analyst rating
- 2.5 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $48.2B (−0.22%)
- Net income
- $7.1B
- Diluted EPS
- $3.46
- Free cash flow
- $12.8B
From the company’s annual report on SEC EDGAR.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.
Headquarters: Princeton, United States · 32,500 employees · bms.com